{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74"}]}],"title":"Responder"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Non-Responder"}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"description":"A patient who achieves a complete or partial response, defined a reduction of at least 65% in tumor size after induction chemotherapy will be considered to have experienced response.","groups":[{"description":"Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC \\> 750/L and platelets \\> 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.\n\ncarboplatin: Given IV\n\netoposide: Given IV\n\nifosfamide: Given IV\n\nthiotepa: Given IV\n\nadjuvant therapy\n\nconventional surgery\n\nneoadjuvant therapy\n\nperipheral blood stem cell transplantation\n\nradiation therapy: craniospinal irradiation","id":"OG000","title":"Radiation Therapy (CR From Induction)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Of the 102 eligible patients, 85 completed induction chemotherapy with sufficient data to assess response. Central review response assessment is used.","reportingStatus":"POSTED","timeFrame":"18 weeks","title":"Response to Induction Chemotherapy","type":"PRIMARY","unitOfMeasure":"Participants"}